Cannabidiol or CBD has been appeared to enhance the manifestations of various conditions, for example, depression, chronic pain, cancers, heart disease, among others. Now, specialists are leading more investigations into how cannabidiol can enhance liver damage.
Common types of the liver disease include hepatitis A, B, C, D, and E. Others are liver Wilson’s disease, bile duct cancer, hyperoxaluria, hemochromatosis, cirrhosis and liver adenoma. Liver disease can be caused by infections, genetics, or alcohol abuse.
It is known that the human body has various cannabinoid receptors, CB1 and CB2, which tie to the CBD molecules and make an arrangement of responses that are beneficial for our body’s procedures. CB1 and CB2 receptors form together with the endocannabinoid (EC) system. CBD blocks off or switches CB1 receptors enacted by liver harm or malady. This slows down the inflammation process in the liver. It additionally prompts the reduction of oxidative stress that can cause the death of liver cells.
Researchers have demonstrated that CBD is a compound that can do wonders for the human body.
In an investigation distributed in the British Journal of Pharmacology, scientists prompt hepatic failure in mice utilizing thioacetamide. They were given non-psychoactive cannabidiol from cannabis. After 12 days, specialists observed that the liver capacity improved. (1)
A study (2) made by Fouad AA and Jresat I. from the department of biomedical sciences, pharmacology division, Saudi Arabia showed that cannabidiol represents a potential therapeutic option to protect the liver against hypoxia-reoxygenation injury.
Another study (3), made in 2011, proved that cannabidiol restores liver function, normalizes 5-HT levels and improves brain pathology in accordance with normalization of brain function.
In conclusion, CBD has a bright future as a solution for a variety of liver diseases and people that suffer from various liver diseases could have a chance to live a normal life if CBD will be considered a viable solution.
This article was written by an independent and third-party author specialising in CBD, hemp and cannabis research. Any opinion, advice or recommendation expressed in the article does not reflect the opinion of Formula Swiss AG or any of our employees. We do not make any claims about any of our products and refer to our disclaimer for more information.